<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071404</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-INF-2020-01</org_study_id>
    <nct_id>NCT05071404</nct_id>
  </id_info>
  <brief_title>Efficacy Assessment and Monitoring of Subcutaneous Infliximab Levels.</brief_title>
  <acronym>Infliximab</acronym>
  <official_title>Efficacy Assessment and Monitoring of Subcutaneous Infliximab Levels in Patients With Inflammatory Bowel Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective observational study in which the efficacy of infliximab is studied in patients&#xD;
      with inflammatory bowel disease and its subcutaneous levels are monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective observational study in which the efficacy of infliximab is studied in patients&#xD;
      with inflammatory bowel disease and its subcutaneous levels are monitored.&#xD;
&#xD;
      Treatment is prior to and independent of the patient's participation in the study and is&#xD;
      governed by clinical judgment criteria and routine clinical practice, not performing any&#xD;
      diagnostic or follow-up intervention that is not routine clinical practice.&#xD;
&#xD;
      Patients are older than 14 years who suffer from inflammatory bowel disease and who receive&#xD;
      remsima as routine treatment.&#xD;
&#xD;
      The source of information will be the patient's medical history.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perform an efficacy assessment and monitoring of subcutaneous infliximab levels in patients with inflammatory bowel disease.</measure>
    <time_frame>Up to 16 weeks.</time_frame>
    <description>Number of hospitalizations of patients treated with subcutaneous infliximab suffering from inflammatory bowel disease.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients treated with infliximab sc.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inflammatory bowel disease over 14 years of age who are being treated with&#xD;
        infliximan sc.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with inflammatory bowel disease.&#xD;
&#xD;
          -  Over 14 years old.&#xD;
&#xD;
          -  Receive Remsin as a treatment for his disease. And always this treatment that the&#xD;
             patient is going to receive is governed by the criteria of clinical judgment and&#xD;
             routine clinical practice, not performing any diagnostic or follow-up intervention&#xD;
             that is not routine clinical practice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inflammatory bowel disease under 14 years of age.&#xD;
&#xD;
          -  Or older than this age with inflammatory bowel disease who do not attend the&#xD;
             established check-ups&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Arguelles Arias</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

